MyMD Pharmaceuticals, Inc.
(NASDAQ : AKER)

( )
AKER PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Medical Specialties
symbolcompany%chnglast%shortavg$volume
DHRDanaher Corp. -1.53%321.510.7%$882.54m
TMOThermo Fisher Scientific, Inc. -2.41%633.151.0%$857.83m
ABTAbbott Laboratories -1.89%125.610.8%$662.68m
MDTMedtronic Plc -3.24%106.710.6%$623.96m
ISRGIntuitive Surgical, Inc. -3.11%324.340.8%$451.92m
DXCMDexCom, Inc. -1.48%562.597.8%$377.07m
BDXBecton, Dickinson & Co. -2.68%237.091.0%$363.70m
BSXBoston Scientific Corp. -1.63%37.961.0%$342.68m
ALGNAlign Technology, Inc. -3.62%611.536.4%$321.01m
SYKStryker Corp. -2.85%236.561.3%$305.17m
EWEdwards Lifesciences Corp. -3.13%107.240.4%$256.34m
AAgilent Technologies, Inc. -1.65%150.891.6%$245.52m
IDXXIDEXX Laboratories, Inc. -3.68%608.073.8%$230.32m
ZBHZimmer Biomet Holdings, Inc. -3.17%119.591.7%$221.27m
WSTWest Pharmaceutical Services, Inc. -1.01%442.861.6%$189.13m

Company Profile

MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which engages in the development of drug products targeting aging and age-related, and autoimmune diseases; chronic pain, anxiety, and sleep disorders. It focuses on developing and commercializing MyMD-1 and SUPERA-CBD therapeutic platforms. MyMD-1 is a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune diseases. Supera-CBD is a synthetic derivative of cannabidiol being developed to treat condition such as epilepsy, pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in Baltimore, MD.